Guselkumab Efficacy and Tolerability in PsA/PsO Save

New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.  

In the double-blind, placebo-controlled, multicenter study from Dr. Deodhar et al, 149 patients with active PsA and ≥3% BSA of plaque psoriasis were randomized to receive GUS or PBO despite prior TNFi history. At week16 non-responders could escape to open-label ustekinumab. At week 24, all remaining PBO patients crossed-over to receive GUS 100 mg

All endpoints were met including the primary endpoint of reaching an ACR20 at week 24.

As expected infections were the most common AEs. Two patient had SAEs (1 knee injury and 1 myocardial infarction). There were no serious infections, malignancies, or deaths through week 24.

GUS was well tolerated and demonstrated improvement in joint symptoms, PsO, enthesitis, dactylitis, and QOL measures in patients with active PsA and ≥3% BSA of psoriasis.